The quarantine authorities announced today (21st) that the COVID-19 oral treatment and injections are effective against 4 sub-mutations of Omicron, including BA.5, which is currently dominant.
Additional trials are currently underway to determine whether the treatment is also effective against the new sub-mutation BA.2.57 (aka Centaur).
The National Institute of Infectious Diseases, the National Institute of Health, at a regular briefing today at the Central Quarantine Countermeasures Headquarters (Bangdaebon), confirmed the efficacy of the Corona 19 treatment against 4 types of sub-displacement viruses including BA.5, BA.4, BA.2.3, and BA.12. announced that it has been confirmed to be maintained.
The National Institute of Infectious Diseases analyzed the efficacy of sub-mutation of Omicron with three types of antiviral drugs for COVID-19 in use in Korea: Paxrovid, Lagevrio, and Vecluri.
As a result, the oral treatment drugs Paxrovid and LaGebrio, and the injectable drug Vecluri, all maintained their antiviral efficacy against the existing virus (delta mutant) for 4 sub-mutations of Omicron.
This therapeutic efficacy assay was conducted at the cellular level.
Kwon Jun-wook, head of the National Institutes of Health, said, "Even though it is a cell-level experiment, we expect that the treatment will be effective when administered at the right time to confirmed patients."
In addition, the New England Journal of Medicine research team announced similar results on the same day that several COVID-19 treatments have efficacy against sub-mutations of Omicron as a result of cell-level analysis, the quarantine authorities introduced.
Efficacy assays are currently in progress for the newly emerged BA.2.75.
Director Kwon Jun-wook said, "Efficacy tests are carried out quickly whenever a new mutation appears, centering on the National Institute of Infectious Diseases." It will take some time and the results will be announced separately.”